Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: The Losartan Intervention for Endpoint reduction in hypertension study

Hypertension

Volumn 45, Issue 1, 2005, Pages 46-52

  Kizer, Jorge R ^a,p   Dahlöf, Björn ^b   Kjeldsen, Sverre E ^c   Julius, Stevo ^d   Beevers, Gareth ^e   De Faire, Ulf ^f   Fyhrquist, Frej ^g   Ibsen, Hans ^h   Kristianson, Krister ⁱ   Lederballe Pedersen, Ole ^j   Lindholm, Lars H ^k   Nieminen, Markka S ^g   Omvik, Per ^l   Oparil, Suzanne ^m   Wedel, Hans ⁿ   Wachtell, Kristian ^p   Edelman, Jonathan M ^p   Snapinn, Steven M ^o   Harris, Katherine E ^o   Devereux, Richard B ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF MICHIGAN   (United States)

^e CITY HOSPITAL   (United Kingdom)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

ⁱ Merck Research Laboratories Scandinavia   (Sweden)

^j VIBORG HOSPITAL   (Denmark)

^k UMEÅ UNIVERSITY   (Sweden)

^l HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^m UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁿ NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^o MERCK RESEARCH LABORATORIES   (United States)

^p Box 222 ^*

more..

Author keywords

Angiotensin antagonists; Clinical trials; Drug therapy; Hypertrophy; Population; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; WARFARIN;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; BRAIN EMBOLISM; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; ETHNOLOGY; EXERCISE; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROLOGICAL COMPLICATION; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STATISTICAL ANALYSIS; STROKE;

AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; ATENOLOL; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; COMORBIDITY; DIABETES COMPLICATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INCIDENCE; LOSARTAN; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 19944428946     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000151324.05355.1c     Document Type: Article

References (31)

1. Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause, 1990-2020: Global Burden of Disease Study. Lancet. 1997;349:1498-1504.
2. Warlow CP. Epidemiology of stroke. Lancet. 1998;352:1-4.
3. American Heart Association. Heart Disease and Stroke Statistics - 2004 Update. Dallas, Tex: American Heart Association; 2004.
4. Bronner LL, Kanter DS, Manson JE. Primary prevention of stroke. N Engl J Med. 1995;333:1392-1400.
5. Kjeldsen SE, Julius S, Hedner T, Hansson L. Stroke is more common than myocardial infarction in hypertension: analysis based on 11 major randomized intervention trials. Blood Press. 2001;10:190-192.
6. Mulrow C, Lau J, Cornell J, Brand M. Pharmacotherapy for hypertension in the elderly. Cochrane Database Syst Rev. 2000:CD000028.
7. MacMahon S, Rodgers A. Blood pressure, antihypertensive treatment and stroke risk. J Hypertens. 1994;12:S5-S14.
8. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents. J Am Med Assoc. 2003;289:2534-2544.
9. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
10. Dahlof B, Devereux RB, Julius S, Kjeldsen SE, Beevers G, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm L, Nieminen MS, Omvik P, Oparil S, Wedel H. Characteristics of 9194 patients with left ventricular hypertrophy. The LIFE Study. Hypertension. 1998;32:989-997.
11. Wolf PA, D'Agostino RB, O'Neal A, Sytkowski P, Kase CS, Belanger AJ, Kannel WB. Secular trends in stroke incidence and mortality. The Framingham Study. Stroke. 1992;23:1551-1555.
12. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Aurup P, Edelman J, Snapinn S. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-1010.
13. Kjeldsen SE, Dahlof B, Devereux RB, Julius S, Aurup P, Edelman J, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn S, Wedel H. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension. J Am Med Assoc. 2002;288:1491-1498.
14. Devereux RB, Dahlof B, Kjeldsen SE, Julius S, Aurup P, Beevers G, Edelman JM, de Faire U, Fyhrquist F, HelleBerg S, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn S, Wedel H. Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease. A substudy of the LIFE randomized trial. Ann Intern Med. 2003;139:169-177.
15. Julius S, Alderman MH, Beevers G, Dahlof B, Devereux RB, Douglas JG, Edelman JM, Harris KE, Kjeldsen SE, Nesbitt S, Randall OS, Wright JT. Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy. J Am Coll Cardiol. 2004;43:1047-1055.
16. Wright JT. Profile of systemic hypertension in black patients. Am J Cardiol 1988;61:41H-45H.
17. Hall WD. Pharmacologic therapy of hypertension in blacks. J Clin Hypertens. 1987;3(suppl 3):108S-113S.
18. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
19. Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, Davies R, Ostergren J, Probstfield J, Use of ramipril in preventing stroke: double blind randomised trial. BMJ. 2992;324:1-5.
20. Sleight P, Yusuf S, Pogue J, Tsuyuki R, Diaz R, Probstfield J. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet. 2001;358:2130-2131.
21. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures. A HOPE Substudy. Hypertension. 2001;38:e28-e32.
22. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. J Am Med Assoc. 2002;288:2981-2997.
23. Wing LMH, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GLR, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583-592.
24. Tobian L, Lange JM, Ulm KM, Wold LJ, Iwai J. Potassium prevents death from strokes in hypertensive rats without lowering blood pressure. J Hypertens. 1984;2(suppl 3):363-366.
25. Stier CT, Chander P, Gutstein WH, Levine S, Itskovitz HD. Therapeutic benefit of captopril in salt-loaded stroke-prone spontaneously hypertensive rats is independent of hypotensive effect. Am J Hypertens. 1991;4:680-687.
26. Camargo MJF, von Lutterotti N, Campbell WG, Pecker MS, James GD, Timmermans PB, Laragh JH. Control of blood pressure and end-organ damage in maturing salt-loaded stroke-prone spontaneously hypertensive rats by oral angiotensin II receptor blockade. J Hypertens. 1993;11:31-40.
27. Stier CT, Adler LA, Levins S, Chander PN. Stroke prevention by losartan in stroke-prone spontaneously hypertensive rats. J Hypertens. 1993;11(suppl 3):S37-S42.
28. Achard JM, Fournier A, Mazouz H, Cardie VJ, Penar PL, Fernandez LA. Protection against ischemia: a physiological function of the renin-angiotensin system. Biochem Pharm. 2001;62:261-271.
29. Verdecchia P, Porcellati C, Reboldi G, Gattobigio R, Borgioni C, Pearson TA, Ambrosio G. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation. 2001;104:2039-2044.
30. Tsang TS, Gersh BJ, Appleton CP, Tajik AJ, Barnes ME, Bailey KR, Oh JK, Leibson C, Montgomery SC, Seward JB. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol. 2002;40:1636-1644.
31. Dahlof B, Burke TA, Krobot K, Carides GW, Edelman JM, Devereux RB, Diener HC. Population impact of losartan use on stroke in the European Union (EU): Projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. J Hum Hypertens. 2004;18:367-373.